Michael Heuser

List of Publications by Year
in descending order

305 papers	16,882 citations	18482 62 h-index	18130 120 g-index
319 all docs	319 docs citations	319 times ranked	16759 citing authors

#	Article	IF	Citations
1	Genomic Classification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine, 2016, 374, 2209-2221.	27.0	3,067
2	Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2018, 131, 1275-1291.	1.4	796
3	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Leukemia, 2019, 33, 379-389.	7.2	396
4	Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood, 2012, 119, 3578-3584.	1.4	391
5	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	30.7	372
6	Incidence and Prognostic Influence of DNMT3A Mutations in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 2889-2896.	1.6	351
7	2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood, 2021, 138, 2753-2767.	1.4	305
8	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
9	Prognostic Significance ofASXL1Mutations in Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2011, 29, 2499-2506.	1.6	258
10	How I treat refractory and early relapsed acute myeloid leukemia. Blood, 2015, 126, 319-327.	1.4	245
11	Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood, 2018, 132, 1703-1713.	1.4	237
12	Impact of IDH1 R132 Mutations and an IDH1 Single Nucleotide Polymorphism in Cytogenetically Normal Acute Myeloid Leukemia: SNP rs11554137 Is an Adverse Prognostic Factor. Journal of Clinical Oncology, 2010, 28, 2356-2364.	1.6	229
13	Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nature Genetics, 2017, 49, 332-340.	21.4	229
14	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood, 2019, 133, 840-851.	1.4	228
15	High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood, 2006, 108, 3898-3905.	1.4	217
16	Human Î³Î´ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection. Nature Immunology, 2017, 18, 393-401.	14.5	208
17	RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia, 2016, 30, 2160-2168.	7.2	197
18	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	7.2	195

#	Article	IF	Citations
19	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	1.4	195
20	Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood, 2013, 122, 2877-2887.	1.4	186
21	Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma. Blood, 2013, 122, 2443-2452.	1.4	178
22	IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica, 2010, 95, 1668-1674.	3.5	177
23	Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood, 2010, 116, 614-616.	1.4	170
24	Mutations in the cohesin complex in acute myeloid leukemia: clinical and prognostic implications. Blood, 2014, 123, 914-920.	1.4	167
25	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2019, 37, 375-385.	1.6	163
26	In-depth characterization of the microRNA transcriptome in a leukemia progression model. Genome Research, 2008, 18, 1787-1797.	5.5	162
27	Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood, 2013, 121, 4769-4777.	1.4	162
28	Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Molecular Therapy, 2017, 25, 165-180.	8.2	149
29	RIPK3 Restricts Myeloid Leukemogenesis by Promoting Cell Death and Differentiation of Leukemia Initiating Cells. Cancer Cell, 2016, 30, 75-91.	16.8	144
30	Myelodysplastic syndromes are induced by histone methylationÃ¢â‚¬â€œaltering ASXL1 mutations. Journal of Clinical Investigation, 2013, 123, 4627-4640.	8.2	140
31	MN1 overexpression induces acute myeloid leukemia in mice and predicts ATRA resistance in patients with AML. Blood, 2007, 110, 1639-1647.	1.4	133
32	Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2015, 16, 1025-1036.	10.7	129
33	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	1.4	127
34	Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation. Blood, 2019, 133, 2233-2242.	1.4	121
35	Single Nucleotide Polymorphism in the Mutational Hotspot of WT1 Predicts a Favorable Outcome in Patients With Cytogenetically Normal Acute Myeloid Leukemia. Journal of Clinical Oncology, 2010, 28, 578-585.	1.6	119
36	Nextâ€generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3â€ITD or NPM1 mutations. Genes Chromosomes and Cancer, 2012, 51, 689-695.	2.8	114

#	Article	IF	Citations
37	Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). Annals of Hematology, 2017, 96, 1993-2003.	1.8	108
38	Loss of Mll5 results in pleiotropic hematopoietic defects, reduced neutrophil immune function, and extreme sensitivity to DNA demethylation. Blood, 2009, 113, 1432-1443.	1.4	101
39	Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood, 2011, 117, 4561-4568.	1.4	99
40	Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia, 2016, 30, 1672-1681.	7.2	99
41	Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo. Leukemia, 2017, 31, 2020-2028.	7.2	97
42	Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients. Blood, 2019, 133, 1140-1151.	1.4	96
43	Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood, 2021, 137, 3093-3104.	1.4	91
44	Comprehensive analysis of mammalian miRNA* species and their role in myeloid cells. Blood, 2011, 118, 3350-3358.	1.4	90
45	Genetic Deletion of SEPT7 Reveals a Cell Type-Specific Role of Septins in Microtubule Destabilization for the Completion of Cytokinesis. PLoS Genetics, 2014, 10, e1004558.	3.5	90
46	A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations. British Journal of Haematology, 2015, 169, 694-700.	2.5	90
47	Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2017, 23, 1095-1101.	2.0	89
48	Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects. Clinical Cancer Research, 2015, 21, 2388-2398.	7.0	88
49	Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation. Nature Communications, 2019, 10, 2031.	12.8	87
50	ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica, 2015, 100, 324-330.	3.5	86
51	Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group. Blood, 2019, 134, 1608-1618.	1.4	85
52	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	1.4	85
53	SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia, 2012, 26, 1137-1140.	7.2	83
54	Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemiaâ€"results of the AMLSG 11-08 trial. Leukemia, 2018, 32, 1621-1630.	7.2	81

#	Article	IF	Citations
55	Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia, 2017, 31, 1306-1313.	7.2	78
56	Cell of Origin in AML: Susceptibility to MN1-Induced Transformation Is Regulated by the MEIS1/AbdB-like HOX Protein Complex. Cancer Cell, 2011, 20, 39-52.	16.8	76
57	Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AMLâ€“BFM and DCOG study groups. Leukemia, 2011, 25, 1704-1710.	7.2	73
58	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. Journal of Clinical Oncology, 2020, 38, 623-632.	1.6	73
59	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood, 2020, 136, 3041-3050.	1.4	73
60	Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal. Blood, 2009, 114, 3983-3993.	1.4	69
61	Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica, 2011, 96, 1870-1873.	3.5	67
62	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1007-1016.	1.6	67
63	Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica, 2005, 90, 1484-92.	3.5	67
64	Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML. Blood, 2012, 119, e96-e99.	1.4	65
65	Clonal Hematopoiesis of Indeterminate Potential. Deutsches Ärzteblatt International, 2016, 113, 317-22.	0.9	65
66	Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene, 2018, 37, 5269-5280.	5.9	65
67	Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 Ã— 2, Phase II Trial. Journal of Clinical Oncology, 2020, 38, 257-270.	1.6	63
68	Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia, 2021, 35, 62-74.	7.2	63
69	Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Annals of Hematology, 2013, 92, 747-758.	1.8	61
70	miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovascular Research, 2016, 110, 215-226.	3.8	61
71	Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo. Annals of Hematology, 2019, 98, 1905-1918.	1.8	61
72	SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia, 2013, 27, 2072-2075.	7.2	60

#	Article	IF	Citations
73	Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations. Blood Advances, 2021, 5, 2294-2304.	5.2	60
74	Linkage of Meis1 leukemogenic activity to multiple downstream effectors including Trib2 and Ccl3. Experimental Hematology, 2008, 36, 845-859.	0.4	56
75	Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation. Leukemia, 2014, 28, 1552-1555.	7.2	56
76	Prognostic Importance of Histone MethyltransferaseMLL5Expression in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2011, 29, 682-689.	1.6	53
77	Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype. Haematologica, 2018, 103, e17-e20.	3.5	53
78	High-affinity neurotrophin receptors and ligands promote leukemogenesis. Blood, 2009, 113, 2028-2037.	1.4	51
79	Genetic characterization of acquired aplastic anemia by targeted sequencing. Haematologica, 2014, 99, e165-e167.	3.5	51
80	Impact of the revised International Prognostic Scoring System, cytogenetics and monosomal karyotype on outcome after allogeneic stem cell transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia evolving from myelodysplastic syndromes: a retrospective multicenter study of the European Society of Blood and Marrow Transplantation. Haematologica, 2015, 100, 400-408.	3.5	50
81	DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia, 2018, 32, 30-37.	7.2	50
82	Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia, 2017, 31, 1217-1220.	7.2	49
83	Individual outcome prediction for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia from MDS after allogeneic hematopoietic cell transplantation. Annals of Hematology, 2017, 96, 1361-1372.	1.8	49
84	Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia. Annals of Hematology, 2013, 92, 315-323.	1.8	48
85	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood, 2020, 136, 387-400.	1.4	46
86	FLT3-internal tandem duplication and age are the major prognostic factors in patients with relapsed acute myeloid leukemia with normal karyotype. Haematologica, 2011, 96, 681-686.	3.5	45
87	Epigenetics in myelodysplastic syndromes. Seminars in Cancer Biology, 2018, 51, 170-179.	9.6	45
88	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Advances, 2020, 4, 6342-6352.	5.2	45
89	Acute myeloid leukemia derived from lympho-myeloid clonal hematopoiesis. Leukemia, 2017, 31, 1286-1295.	7.2	44
90	Germline variants drive myelodysplastic syndrome in young adults. Leukemia, 2021, 35, 2439-2444.	7.2	43

#	Article	IF	Citations
91	Analysis of NUP98/NSD1 translocations in adult AML and MDS patients. Leukemia, 2013, 27, 750-754.	7.2	42
92	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	7.2	42
93	An open-label, Phase I study of cediranib (RECENTINâ„¢) in patients with acute myeloid leukemia. Leukemia Research, 2010, 34, 196-202.	0.8	40
94	Distinct splicing signatures affect converged pathways in myelodysplastic syndrome patients carrying mutations in different splicing regulators. Rna, 2016, 22, 1535-1549.	3.5	40
95	Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia, 2016, 30, 1708-1715.	7.2	38
96	Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results. Leukemia, 2020, 34, 2903-2913.	7.2	38
97	Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromes. Annals of Hematology, 2012, 91, 1221-1233.	1.8	37
98	Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication. Annals of Hematology, 2011, 90, 1047-1058.	1.8	36
99	Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemia. Leukemia, 2012, 26, 289-295.	7.2	36
100	Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group. Leukemia, 2016, 30, 2248-2250.	7.2	36
101	Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killerâ€“Based â€œOff-the-Shelfâ€•Acute Myeloid Leukemia Immunotherapies. Human Gene Therapy, 2019, 30, 381-401.	2.7	36
102	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. Blood, 2016, 128, 99-99.	1.4	36
103	DNMT3A mutations are rare in childhood acute myeloid leukemia. Haematologica, 2011, 96, 1238-1240.	3.5	34
104	Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial. Blood Advances, 2020, 4, 4945-4954.	5.2	34
105	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	2.5	34
106	Functional role of BAALC in leukemogenesis. Leukemia, 2012, 26, 532-536.	7.2	33
107	Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia. Annals of Hematology, 2013, 92, 1079-1090.	1.8	33
108	Use of Colony-Stimulating Factors for Chemotherapy-Associated Neutropenia: Review of Current Guidelines. Seminars in Hematology, 2007, 44, 148-156.	3.4	32

#	Article	IF	Citations
109	Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?. Hematology American Society of Hematology Education Program, 2016, 2016, 24-32.	2.5	32
110	Midostaurin in Combination with Intensive Induction and As Single Agent Maintenance Therapy after Consolidation Therapy with Allogeneic Hematopoietic Stem Cell Transplantation or High-Dose Cytarabine (NCT01477606). Blood, 2015, 126, 322-322.	1.4	32
111	Colony-stimulating factors in the management of neutropenia and its complications. Annals of Hematology, 2005, 84, 697-708.	1.8	30
112	Therapy-related myeloid neoplasms. Current Opinion in Hematology, 2017, 24, 152-158.	2.5	30
113	IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunctionâ€"a retrospective propensity score analysis. Leukemia, 2021, 35, 1301-1316.	7.2	30
114	KIT D816 mutated/CBF-negative acute myeloid leukemia: a poor-risk subtype associated with systemic mastocytosis. Leukemia, 2019, 33, 1124-1134.	7.2	29
115	Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia. Haematologica, 2021, 106, 565-573.	3.5	29
116	Targeted Inhibition of the NUP98-NSD1 Fusion Oncogene in Acute Myeloid Leukemia. Cancers, 2020, 12, 2766.	3.7	29
117	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	6.2	29
118	Linkage of the potent leukemogenic activity of Meis1 to cell-cycle entry and transcriptional regulation of cyclin D3. Blood, 2010, 115, 4071-4082.	1.4	28
119	MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemia. Experimental Hematology, 2015, 43, 858-868.e7.	0.4	28
120	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy. Journal of Hematology and Oncology, 2020, 13, 92.	17.0	28
121	TET2 mutations in cytogenetically normal acute myeloid leukemia: Clinical implications and evolutionary patterns. Genes Chromosomes and Cancer, 2014, 53, 824-832.	2.8	27
122	FLAâ€IDA salvage chemotherapy combined with a sevenâ€day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia. British Journal of Haematology, 2020, 188, e11-e15.	2.5	27
123	Clinical benefit of glasdegib plus low-dose cytarabine in patients with de novo and secondary acute myeloid leukemia: long-term analysis of a phase II randomized trial. Annals of Hematology, 2021, 100, 1181-1194.	1.8	27
124	Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia. Haematologica, 2014, 99, 1456-1464.	3.5	26
125	Treatment for Relapsed/Refractory Acute Myeloid Leukemia. HemaSphere, 2021, 5, e572.	2.7	26
126	Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype. BMC Genomics, 2014, 15, 784.	2.8	25

#	Article	IF	Citations
127	Constitutive IRF8 expression inhibits AML by activation of repressed immune response signaling. Leukemia, 2015, 29, 157-168.	7.2	25
128	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. Biomaterials, 2017, 139, 102-115.	11.4	24
129	Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Advances, 2022, 6, 5345-5355.	5.2	24
130	Modeling de novo leukemogenesis from human cord blood with MN1 and NUP98HOXD13. Blood, 2014, 124, 3608-3612.	1.4	23
131	Enigmas of IDH mutations in hematology/oncology. Experimental Hematology, 2015, 43, 685-697.	0.4	22
132	Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer. Expert Opinion on Therapeutic Targets, 2018, 22, 107-121.	3.4	22
133	A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation. Blood Advances, 2021, 5, 1760-1769.	5.2	22
134	Update on cytogenetic and molecular changes in myelodysplastic syndromes. Leukemia and Lymphoma, 2012, 53, 525-536.	1.3	21
135	All-in-One inducible lentiviral vector systems based on drug controlled FLP recombinase. Biomaterials, 2014, 35, 4345-4356.	11.4	21
136	Gfi1b: a key player in the genesis and maintenance of acute myeloid leukemia and myelodysplastic syndrome. Haematologica, 2018, 103, 614-625.	3.5	21
137	Clinical and functional implications of microRNA mutations in a cohort of 935 patients with myelodysplastic syndromes and acute myeloid leukemia. Haematologica, 2015, 100, e122-e124.	3.5	20
138	Generation of Genetically Engineered Precursor T-Cells From Human Umbilical Cord Blood Using an Optimized Alpharetroviral Vector Platform. Molecular Therapy, 2016, 24, 1216-1226.	8.2	20
139	Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia. Leukemia, 2019, 33, 1313-1323.	7.2	20
140	Reduced intensity hematopoietic stem cell transplantation forÂaccelerated-phase myelofibrosis. Blood Advances, 2022, 6, 1222-1231.	5.2	20
141	Recombinant human erythropoietin in the treatment of nonrenal anemia. Annals of Hematology, 2006, 85, 69-78.	1.8	19
142	ASXL1/EZH2 mutations promote clonal expansion of neoplastic HSC and impair erythropoiesis in PMF. Leukemia, 2019, 33, 99-109.	7.2	19
143	Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q. Leukemia, 2015, 29, 1942-1945.	7.2	18
144	MicroRNA-155 is upregulated in MLL-rearranged AML but its absence does not affect leukemia development. Experimental Hematology, 2016, 44, 1166-1171.	0.4	18

#	Article	IF	Citations
145	All-Trans Retinoic Acid Improves Outcome in Younger Adult Patients with Nucleophosmin-1 Mutated Acute Myeloid Leukemia â€“ Results of the AMLSG 07-04 Randomized Treatment Trial. Blood, 2011, 118, 80-80.	1.4	18
146	Impact of Age and Midostaurin-Dose on Response and Outcome in Acute Myeloid Leukemia with FLT3-ITD: Interim-Analyses of the AMLSG 16-10 Trial. Blood, 2016, 128, 449-449.	1.4	18
147	Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening. Current Cancer Drug Targets, 2016, 16, 818-828.	1.6	17
148	Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. Experimental Hematology, 2016, 44, 713-726.e14.	0.4	16
149	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 411-420.	3.8	16
150	Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123. Viruses, 2021, 13, 1365.	3.3	16
151	RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo. Leukemia, 2018, 32, 224-226.	7.2	15
152	Cell Fate Decisions in Malignant Hematopoiesis: Leukemia Phenotype Is Determined by Distinct Functional Domains of the MN1 Oncogene. PLoS ONE, 2014, 9, e112671.	2.5	15
153	Myeloid growth factors in acute myeloid leukemia: systematic review of randomized controlled trials. Annals of Hematology, 2011, 90, 273-281.	1.8	14
154	Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group. Leukemia, 2017, 31, 1012-1015.	7.2	14
155	A Phase II study of selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia. British Journal of Haematology, 2020, 190, e169-e173.	2.5	14
156	Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization. Haematologica, 2017, 102, e170-e174.	3.5	13
157	In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia, 2020, 34, 416-426.	7.2	13
158	Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia, 2020, 34, 2951-2963.	7.2	13
159	Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation. European Journal of Haematology, 2019, 103, 552-557.	2.2	12
160	Emerging strategies to target the dysfunctional cohesin complex in cancer. Expert Opinion on Therapeutic Targets, 2019, 23, 525-537.	3.4	12
161	Long-Term Survival Benefit after Allogeneic Hematopoietic Cell Transplantation for Chronic Myelomonocytic Leukemia. Transplantation and Cellular Therapy, 2021, 27, 95.e1-95.e4.	1.2	12
162	A first-in-patient phase I study of BGB324, a selective Axl kinase inhibitor in patients with refractory/relapsed AML and high-risk MDS.. Journal of Clinical Oncology, 2016, 34, 2561-2561.	1.6	12

#	Article	IF	Citations
163	Results of the Randomized Phase II Study Decider (AMLSG 14-09) Comparing Decitabine (DAC) with or without Valproic Acid (VPA) and with or without All-Trans Retinoic Acid (ATRA) Add-on in Newly Diagnosed Elderly Non-Fit AML Patients. Blood, 2016, 128, 589-589.	1.4	11
164	Cytotoxicity determination without photochemical artifacts. Cancer Letters, 2005, 223, 57-66.	7.2	10
165	Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-Î±2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation. Cancer Immunology, Immunotherapy, 2019, 68, 1891-1899.	4.2	10
166	The Actin Binding Protein Plastin-3 Is Involved in the Pathogenesis of Acute Myeloid Leukemia. Cancers, 2019, 11, 1663.	3.7	10
167	Clonal expansion of CD8+ T cells reflects graft-versus-leukemia activity and precedes durable remission following DLI. Blood Advances, 2021, 5, 4485-4499.	5.2	10
168	Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG). Blood, 2016, 128, 1207-1207.	1.4	10
169	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation. PLoS ONE, 2017, 12, e0183828.	2.5	10
170	Activation of TRKA receptor elicits mastocytosis in mice and is involved in the development of resistance to KIT-targeted therapy. Oncotarget, 2017, 8, 73871-73883.	1.8	10
171	A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2. Journal of Medicinal Chemistry, 2022, 65, 1171-1205.	6.4	10
172	<scp>ID</scp>1 expression associates with other molecular markers and is not an independent prognostic factor in cytogenetically normal acute myeloid leukaemia. British Journal of Haematology, 2012, 158, 208-215.	2.5	9
173	Newly diagnosed isolated myeloid sarcomaâ€“paired NGS panel analysis of extramedullary tumor and bone marrow. Annals of Hematology, 2021, 100, 499-503.	1.8	9
174	A 2:1 randomized, open-label, phase II study of selinexor vs. physicianâ€™s choice in older patients with relapsed or refractory acute myeloid leukemia. Leukemia and Lymphoma, 2021, 62, 1-12.	1.3	9
175	Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion. International Journal of Molecular Sciences, 2018, 19, 3269.	4.1	8
176	Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. Haematologica, 2020, 105, 1294-1305.	3.5	8
177	Lactonization of the Oncometabolite D-2-Hydroxyglutarate Produces a Novel Endogenous Metabolite. Cancers, 2021, 13, 1756.	3.7	8
178	A Novel Inhibitor of Mutant IDH1 Induces Differentiation in Vivo and Prolongs Survival in a Mouse Model of Leukemia. Blood, 2014, 124, 3598-3598.	1.4	8
179	Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia. Annals of Hematology, 2014, 93, 193-202.	1.8	7
180	The hypomorphic TERT A1062T variant is associated with increased treatment-related toxicity in acute myeloid leukemia. Annals of Hematology, 2017, 96, 895-904.	1.8	7

#	Article	IF	Citations
181	Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset. Frontiers in Immunology, 2017, 8, 1100.	4.8	7
182	Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia. Haematologica, 2018, 103, 246-255.	3.5	7
183	Event-Free Survival Is a Surrogate for Overall Survival in Patients Treated for Acute Myeloid Leukemia. Blood, 2015, 126, 3744-3744.	1.4	7
184	Pan-Mutant-IDH1 Inhibitor Bay-1436032 Is Highly Effective Against Human IDH1 Mutant Acute Myeloid Leukemia In Vivo. Blood, 2016, 128, 745-745.	1.4	7
185	A phase 2 study of azacitidine (5-AZA) with or without birinapant in subjects with higher risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML).. Journal of Clinical Oncology, 2016, 34, 7060-7060.	1.6	7
186	VH1 Family Immunoglobulin Repertoire Sequencing after Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE, 2017, 12, e0168096.	2.5	7
187	Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia. Blood Cancer Discovery, 2022, 3, 410-427.	5.0	7
188	Low frequency of calreticulin mutations in MDS patients. Leukemia, 2014, 28, 1933-1934.	7.2	6
189	Lack of noncanonical RAS mutations in cytogenetically normal acute myeloid leukemia. Annals of Hematology, 2014, 93, 977-982.	1.8	6
190	Letter to the Editor: Production of Mature Healthy Hematopoietic Cells from Induced Pluripotent Stem Cells Derived from an AML Diagnostic Sample Containing the t(8;21) Translocation. Stem Cells, 2016, 34, 797-799.	3.2	6
191	First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.. Journal of Clinical Oncology, 2019, 37, 7043-7043.	1.6	6
192	Extrinsic signals determine myeloid-erythroid lineage switch in MN1 leukemia. Experimental Hematology, 2010, 38, 174-179.	0.4	5
193	Phosphoinositide Phospholipase Cî²1 (PI-PLCî²1) Gene in Myelodysplastic Syndromes and Cytogenetically Normal Acute Myeloid Leukemia: Not a Deletion, but Increased PI-PLCî²1 Expression Is an Independent Prognostic Factor. Journal of Clinical Oncology, 2010, 28, e384-e387.	1.6	5
194	Biologic and experimental variation of measured cancer stem cells. Cell Cycle, 2010, 9, 909-912.	2.6	5
195	Clinical impact of <scp>KMT</scp>2C and <scp>SPRY</scp>4 expression levels in intensively treated younger adult acute myeloid leukemia patients. European Journal of Haematology, 2017, 99, 544-552.	2.2	5
196	Risk of tumor lysis syndrome in patients with acute myeloid leukemia treated with venetoclax-containing regimens without dose ramp-up. Annals of Hematology, 2021, 100, 595-599.	1.8	5
197	Cluster of differentiation 33 single nucleotide polymorphism rs12459419 is a predictive factor in patients with nucleophosmin1 mutated acute myeloid leukemia receiving gemtuzumab ozogamicin. Haematologica, 2021, 106, 2986-2989.	3.5	5
198	Induced dendritic cells co-expressing GM-CSF/IFN-Î±/tWT1 priming T and B cells and automated manufacturing to boost GvL. Molecular Therapy - Methods and Clinical Development, 2021, 21, 621-641.	4.1	5

#	Article	IF	Citations
199	Gemtuzumab Ozogamicin in NPM1-Mutated Acute Myeloid Leukemia (AML): Results from the Prospective Randomized AMLSG 09-09 Phase-III Study. Blood, 2018, 132, 81-81.	1.4	5
200	Molecular Predictors of Outcome in Patients with MDS and AML Following MDS after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 912-912.	1.4	5
201	Reply to I.H.I.M. Hollink et al. Journal of Clinical Oncology, 2010, 28, e527-e528.	1.6	4
202	The Hematopoietic Growth Factors in Acute Leukemia: A European Perspective. Cancer Treatment and Research, 2010, 157, 339-362.	0.5	4
203	Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG). Blood, 2015, 126, 226-226.	1.4	4
204	Low-dose cytarabine with or without glasdegib in newly diagnosed patients with acute myeloid leukemia: Long-term analysis of a phase 2 randomized trial.. Journal of Clinical Oncology, 2019, 37, 7010-7010.	1.6	4
205	First-in-Human Phase I Dose Escalation and Expansion Study Evaluating the Fc Optimized FLT3 Antibody Flysyn in Acute Myeloid Leukemia Patients with Minimal Residual Disease. Blood, 2020, 136, 8-9.	1.4	4
206	Mouse Models of Frequently Mutated Genes in Acute Myeloid Leukemia. Cancers, 2021, 13, 6192.	3.7	4
207	Priming reloaded?. Blood, 2009, 114, 925-926.	1.4	3
208	Oxaliplatin pharmacokinetics on hemodialysis in a patient with diffuse large B cell lymphoma. Annals of Hematology, 2016, 95, 649-650.	1.8	3
209	Rationalization of the Activity Profile of Pyruvate Kinase Isozyme M2 (PKM2) Inhibitors using 3D QSAR. Current Topics in Medicinal Chemistry, 2021, 21, 2258-2271.	2.1	3
210	Monitoring of FLT3 Phosphorylation and FLT3 Ligand Levels in Patients with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Treated with Midostaurin within the AMLSG 16-10 Trial of the German-Austrian Study Group. Blood, 2018, 132, 1501-1501.	1.4	3
211	Ivosidenib Improves Overall Survival Relative to Standard Therapies in Relapsed or Refractory Mutant IDH1 AML: Results from Matched Comparisons to Historical Controls. Blood, 2020, 136, 18-19.	1.4	3
212	Prognostic Effect of Mutations in the Splicing Gene Machinery in 339 Patients with MDS or Secondary AML Following MDS After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2012, 120, 357-357.	1.4	3
213	Pharmacodynamic Analysis Of The Inhibitory Potency Of The Tyrosine Kinase Inhibitor Midostaurin In Combination With Intensive Chemotherapy Including Allogeneic Hematopoietic Stem Cell Transplantation Followed By Maintenance Therapy In FLT3-ITD Positive Acute Myeloid Leukemia In The Ongoing AMLSG 16-10 Trial. Blood, 2013, 122, 1283-1283.	1.4	3
214	Expression Of Hedgehog Pathway Mediator Gli2 Represents a Clinically Negative Prognostic Marker In Acute Myeloid Leukemia and Its Inhibitor GANT61 Exerts Anti-Leukemic Effects In Vitro. Blood, 2013, 122, 53-53.	1.4	3
215	Selinexor, ARA-C and Idarubicin: An Effective and Tolerable Combination in Patients with Relapsed/Refractory AML: A Multicenter Phase II Study. Blood, 2015, 126, 3789-3789.	1.4	3
216	The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408). Blood, 2020, 136, 14-14.	1.4	3

#	Article	IF	Citations
217	Genotype-Phenotype Relationships and Therapeutic Targets in Acute Erythroid Leukemia. Blood, 2020, 136, 17-18.	1.4	3
218	Reply to S. Masuda. Journal of Clinical Oncology, 2011, 29, 4593-4594.	1.6	2
219	Phase I/<scp>II</scp> study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (<scp>AMLSG</scp> 17â€10 <scp>CIARA</scp> trial). British Journal of Haematology, 2018, 183, 235-241.	2.5	2
220	Selection and management of older patients with acute myeloid leukemia treated with glasdegib plus low-dose cytarabine: expert panel review. Leukemia and Lymphoma, 2020, 61, 3287-3305.	1.3	2
221	Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia. Annals of Hematology, 2020, 99, 1415-1417.	1.8	2
222	Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies. Journal of Clinical Pharmacology, 2021, 61, 349-359.	2.0	2
223	Unbalanced translocation der(5;17) resulting in a TP53 loss as recurrent aberration in myelodysplastic syndrome and acute myeloid leukemia with complex karyotype. Genes Chromosomes and Cancer, 2021, 60, 452-457.	2.8	2
224	Impact of <scp>PPM1D</scp> mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. American Journal of Hematology, 2021, 96, E207-E210.	4.1	2
225	Mir-223 Is Dispensable for the Onset of Acute Myeloid Leukemia. Blood, 2010, 116, 501-501.	1.4	2
226	Clinical Impact of TERT A1062T Mutations in Younger Patients with Acute Myeloblastic Leukemia. Blood, 2012, 120, 1381-1381.	1.4	2
227	Effective Treatment of Human CML By RNAi In Vivo in a Xenotransplantation Mouse Model. Blood, 2015, 126, 1261-1261.	1.4	2
228	Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation. Blood, 2015, 126, 352-352.	1.4	2
229	Dissecting Genetic and Phenotypic Heterogeneity to Map Molecular Phylogenies and Deliver Personalized Outcome and Treatment Predictions in AML. Blood, 2015, 126, 803-803.	1.4	2
230	TCR Diversity Is a Predictive Marker for Donor Lymphocyte Infusion Response. Blood, 2016, 128, 4605-4605.	1.4	2
231	Axl blockade in vitro and in patients with high-risk MDS by the small molecule inhibitor BGB324.. Journal of Clinical Oncology, 2017, 35, 7059-7059.	1.6	2
232	Frequency and Prognostic Impact of NUP98/NSD1 Translocations in Adult AML and MDS Patients. Blood, 2012, 120, 1402-1402.	1.4	2
233	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 324-324.	1.4	2
234	Allogeneic, CD34 +, Umbilical Cordblood-Derived NK Cell Adoptive Immunotherapy for the Treatment of Acute Myeloid Leukemia Patients with Measurable Residual Disease. Blood, 2021, 138, 1745-1745.	1.4	2

#	Article	IF	Citations
235	EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia. Blood, 2021, 138, 610-610.	1.4	2
236	Clonal Evolution at First Sight: A Combined Visualization of Diverse Diagnostic Methods Improves Understanding of Leukemic Progression. Frontiers in Oncology, 0, 12, .	2.8	2
237	Genetic changes of miR-182 G106A: rather a polymorphism than a somatic mutation. Annals of Hematology, 2011, 90, 1107-1109.	1.8	1
238	Message from the void: MRD analysis from ctDNA. Blood, 2019, 133, 2631-2633.	1.4	1
239	MN1 Inhibits Myeloid Differentiation by Transcriptional Repression of EGR2. Blood, 2010, 116, 229-229.	1.4	1
240	Results of the â€œEvaluation of NGS in AML-Diagnostics (ELAN)â€•Study â€“ an Inter-Laboratory Comparison Performed in 10 European Laboratories. Blood, 2014, 124, 2374-2374.	1.4	1
241	Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3171-3171.	1.4	1
242	The Metabolite R-2-Hydroxyglutarate (R2HG) Collaborates with HoxA9 to Induce Monocytic Leukemia. Blood, 2014, 124, 366-366.	1.4	1
243	Casein Kinase 1A1 (CSNK1A1) Is Recurrently Mutated in MDS Patients with Deletion of Chromosome 5q. Blood, 2014, 124, 4643-4643.	1.4	1
244	Molecular Characterization of Relapsed Core-Binding Factor (CBF) Acute Myeloid Leukemia (AML). Blood, 2015, 126, 2586-2586.	1.4	1
245	Incidence and Prognostic Relevance of ASXL2 Mutations in Adult CBF-AML with t(8;21)(q22;q22): A Study of the German-Austrian AML Study Group (AMLSG). Blood, 2015, 126, 3818-3818.	1.4	1
246	Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data. Blood, 2015, 126, 85-85.	1.4	1
247	Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.. Journal of Clinical Oncology, 2018, 36, 7020-7020.	1.6	1
248	The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome.. Journal of Clinical Oncology, 2018, 36, 70-70.	1.6	1
249	Comprehensive Profiling of Micrornas in Murine Hematopoietic Stem Cells and Lineages Using a Microfluidics Approach. Blood, 2008, 112, 2468-2468.	1.4	1
250	FLT3-ITD and Age Are the Major Prognostic Factors In Relapsed AML with Normal Karyotype. Blood, 2010, 116, 1719-1719.	1.4	1
251	EZH2 Mutations Are Drivers of Clonal Hematopoiesis and Leukemic Transformation in a Mouse Model of Primary Myelofibrosis. Blood, 2014, 124, 3211-3211.	1.4	1
252	Single Cell Signaling Pharmacodynamics in a Phase 1b Trial of the Axl Inhibitor BGB324 in Acute Myeloid Leukemia. Blood, 2016, 128, 3995-3995.	1.4	1

#	Article	IF	Citations
253	The miRNA-193 Family Is a Potent Tumor-Suppressor and a Biomarker for Poor Prognosis in Acute Myeloid Leukemia. Blood, 2016, 128, 1534-1534.	1.4	1
254	Genetic Profile of Acute Erythroid Leukemia. Blood, 2016, 128, 40-40.	1.4	1
255	Midostaurin Plus Intensive Chemotherapy for Younger and Older Patients with Acute Myeloid Leukemia and FLT3 Internal Tandem Duplications. Blood, 2021, 138, 692-692.	1.4	1
256	Activity of Decitabine (DAC) Combined with All-Trans Retinoic Acid (ATRA) in Oligoblastic AML: Subgroup Analysis of a Randomized 2x2 Phase II Trial. Blood, 2020, 136, 9-10.	1.4	1
257	Increased late non-cardiac non-relapse mortality in patients with atrial fibrillation diagnosed during hospital stay for allogeneic stem cell transplantation. Transplantation and Cellular Therapy, 2022, , .	1.2	1
258	MN1 regulates self-renewal and differentiation through distinct domains. Experimental Hematology, 2013, 41, S52-S53.	0.4	0
259	Gfi1 as a new target and predictive marker in AML. Experimental Hematology, 2014, 42, S20.	0.4	0
260	MP475OXALIPLATIN PHARMACOKINETICS ON HEMODIALYSIS IN A PATIENT WITH DIFFUSE LARGE B-CELL LYMPHOMA. Nephrology Dialysis Transplantation, 2016, 31, i499-i499.	0.7	0
261	The actin binding protein plastin-3 is involved in the pathogenesis of acute myeloid leukemia. Experimental Hematology, 2017, 53, S58.	0.4	0
262	Evidence for a lowâ€penetrant extended phenotype of rhabdoid tumor predisposition syndrome type 1 from a kindred with gain of SMARCB1 exon 6. Pediatric Blood and Cancer, 2021, 68, e29185.	1.5	0
263	Measurable Residual Disease in AML. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S116-S118.	0.4	0
264	Drug-Response Signature Predicts Outcome in Adult Acute Myeloid Leukemia and Associates Poor Response with Molecular Characteristics of Hematopoietic Stem Cells.. Blood, 2004, 104, 2024-2024.	1.4	0
265	MN1 Expression Predicts Prognosis of Acute Myeloid Leukemia with Normal Cytogenetics.. Blood, 2005, 106, 2351-2351.	1.4	0
266	An Open, Phase I Study of Cediranib in Patients with Acute Myeloid Leukemia (AML).. Blood, 2007, 110, 895-895.	1.4	0
267	Neurotrophin Receptors and Ligands Are Highly Expressed in Acute Leukemia and Promote Leukemogenesis.. Blood, 2007, 110, 696-696.	1.4	0
268	A Potent Stimulator of Self-Renewal in Combination with MEIS1 Overexpression Allows the Transformation of Late Committed Myeloid Progenitors.. Blood, 2009, 114, 1434-1434.	1.4	0
269	Functional Role of BAALC In Leukemogenesis. Blood, 2010, 116, 4194-4194.	1.4	0
270	Competition In Engraftment of Normal Hematopoietic Stem Cells and Leukemic Stem Cells. Blood, 2010, 116, 4836-4836.	1.4	0

#	Article	IF	Citations
271	ID1 Expression Correlates with CEBPA Mutational Status and Is Not An Independent Risk Factor in Cytogenetically Normal AML,. Blood, 2011, 118, 3554-3554.	1.4	0
272	Mutations of the Spliceosome Complex Genes Occur In Adult Patients but Are Very Rare In Children with Myeloid Neoplasia. Blood, 2011, 118, 2797-2797.	1.4	0
273	Next Generation Sequencing for Minimal Residual Disease Monitoring in AML Patients with FLT3-ITD,. Blood, 2011, 118, 3548-3548.	1.4	0
274	Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis. Blood, 2012, 120, 1740-1740.	1.4	0
275	Mutated IDH1 Has 2-Hydroxyglutarate-Independent Functions in Leukemogenesis. Blood, 2012, 120, 770-770.	1.4	0
276	Gfi1 As a Novel Prognostic Marker and Tumor Suppressor In Acute Myeloid Leukemia. Blood, 2013, 122, 2516-2516.	1.4	0
277	Analysis Of Micro-RNA-142 Mutations In a Cohort Of 944 Patients With MDS and AML. Blood, 2013, 122, 2804-2804.	1.4	0
278	Minimal Residual Disease (MRD) Monitoring in NPM1 Mutated Acute Myeloid Leukemia (AML): Impact of Concurrent FLT3-ITD and DNMT3A Mutations on MRD Kinetics and Clinical Outcome. Blood, 2013, 122, 2555-2555.	1.4	0
279	Clinical Impact of GATA2 Mutations in Acute Myeloid Leukemia Patients Harboring CEBPA Mutations: A Study of the AML Study Group (AMLSG). Blood, 2013, 122, 1332-1332.	1.4	0
280	The Clinical and Prognostic Influence Of Mutations In The Cohesin Complex In Acute Myeloid Leukemia. Blood, 2013, 122, 1314-1314.	1.4	0
281	Prognostic Value Of Five-Group Cytogenetic Risk Classification In Patients With MDS After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Multicenter Study Of The Chronic Malignancies Working Party Of The EBMT. Blood, 2013, 122, 2092-2092.	1.4	0
282	C-Terminal-Truncating ASXL1 Mutations Induce MDS Via Inhibition Of PRC2. Blood, 2013, 122, 471-471.	1.4	0
283	Dose Dependent Role of Gfi1 in Human MDS and AML and Its Suitability As a Novel Target. Blood, 2014, 124, 777-777.	1.4	0
284	Impact of Donor Type on Outcome after Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients: Analysis of the German-Austrian Acute Myeloid Leukemia Study Group (AMLSG). Blood, 2014, 124, 1254-1254.	1.4	0
285	Hoxa9/Meis1 Mediate Leukemic Programming through Microrna-155. Blood, 2014, 124, 884-884.	1.4	0
286	In Vivo Methylome Changes in Purified Peripheral Blood Blasts and T Cells of AML Patients Treated with Decitabine: Statistical Modelling of a Hypomethylation Response. Blood, 2014, 124, 870-870.	1.4	0
287	High-Throughput Drug Screening Identifies Pyrimethamine As a Potent and Selective Inhibitor of Acute Myeloid Leukemia. Blood, 2014, 124, 2304-2304.	1.4	0
288	Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis. Blood, 2015, 126, 224-224.	1.4	0

#	Article	IF	Citations
289	The Role of microRNA-155 in Mouse Models of MLL -AML. Blood, 2015, 126, 2446-2446.	1.4	0
290	The Mir-193 Family Antagonizes Stem Cell Pathways and Is a Potent Tumor Suppressor in Childhood and Adult Acute Myeloid Leukemia. Blood, 2015, 126, 1244-1244.	1.4	0
291	A Tumor Suppressor microRNA Defines the Leukemic Hierarchy in Acute Myeloid Leukemia. Blood, 2015, 126, 3653-3653.	1.4	0
292	Patient Derived Xenotransplantation Model of Atypical Chronic Myeloid Leukemia (aCML). Blood, 2015, 126, 2836-2836.	1.4	0
293	Clinical Impact of KMT2C and SPRY4 Expression Levels in Intensively Treated Younger Adult Acute Myeloid Leukemia Patients. Blood, 2016, 128, 1663-1663.	1.4	0
294	Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.4	0
295	HSC Hierarchy in Primary Myelofibrosis. Blood, 2016, 128, 4285-4285.	1.4	0
296	T Regulatory Cell Receptor Repertoire Focusing and Clonal Expansion Indicates Control of Acute GvHD after Donor Lymphocyte Infusion. Blood, 2018, 132, 822-822.	1.4	0
297	Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG). Blood, 2019, 134, 2740-2740.	1.4	0
298	Efficacy of Chemotherapy, Phd-Inhibitor Molidustat or BRD4 Inhibitor JQ1 in Combination with Targeted Inhibition of Mutated IDH1 in Human AML In Vivo. Blood, 2019, 134, 3933-3933.	1.4	0
299	Clonal Relapse Dynamics in Acute Myeloid Leukemia Following Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 611-611.	1.4	0
300	IDH Mutations Are Associated with an Increased Risk of Coronary Artery Disease and Cardiotoxicity in Patients with Established AML. Blood, 2020, 136, 32-33.	1.4	0
301	Mutational Landscape of Relapsed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML). Blood, 2020, 136, 42-42.	1.4	0
302	MO343: Deep Analysis of The AKIâ€"CKD in Allogeneic Stem Cell Transplantationâ€"A Big Data Approach. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0
303	Changes in health-related quality of life in patients with newly diagnosed acute myeloid leukemia receiving ivosidenib + azacitidine or placebo + azacitidine.. Journal of Clinical Oncology, 2022, 40, e19024-e19024.	1.6	0
304	Hematologic improvements with ivosidenib + azacitidine compared to placebo + azacitidine in patients with newly diagnosed acute myeloid leukemia.. Journal of Clinical Oncology, 2022, 40, 7042-7042.	1.6	0
305	Molecular characterization of clinical response in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.. Journal of Clinical Oncology, 2022, 40, 7019-7019.	1.6	0